{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:02:06Z","timestamp":1782475326574,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives de P\u00e9diatrie"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.arcped.2025.03.005","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T19:39:56Z","timestamp":1749843596000},"page":"344-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Preliminary proposals for the follow-up of infants born to mothers with cystic fibrosis treated with CFTR modulators during the first two years of life"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9192-8335","authenticated-orcid":false,"given":"Philippe","family":"Reix","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Audousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Girodon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle Sermet","family":"Gaudelus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcped.2025.03.005_bib0001","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis","volume":"402","author":"Taylor-Cousar","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.arcped.2025.03.005_bib0002","unstructured":"Legifrance. Arr\u00eat\u00e9 du 2 juillet 2021 modifiant la liste des sp\u00e9cialit\u00e9s pharmaceutiques remboursables aux assur\u00e9s sociaux [internet]. 2021. Available from: https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000043752654."},{"key":"10.1016\/j.arcped.2025.03.005_bib0003","unstructured":"Fili\u00e8re Muco\/CFTR. [Internet] Registre fran\u00e7ais de la mucoviscidose - Bilan des donn\u00e9es 2023. Available from: https:\/\/www.vaincrelamuco.org\/sites\/default\/files\/registre_2023_-_bilan.pdf."},{"key":"10.1016\/j.arcped.2025.03.005_bib0004","unstructured":"Cystic Fibrosis Foundation. [Internet] Cystic Fibrosis Foundation patient registry highlights Bethesda, Maryland 2024. Available from: https:\/\/www.cff.org\/sites\/default\/files\/2024-06\/2023-Cystic-Fibrosis-Foundation-Patient-Registry-Highlights-Handout.pdf."},{"key":"10.1016\/j.arcped.2025.03.005_bib0005","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jcf.2024.01.001","article-title":"Drug-induced liver injury associated with elexacaftor\/tezacaftor\/ivacaftor: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)","volume":"23","author":"Shi","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.arcped.2025.03.005_bib0006","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1111\/bph.16417","article-title":"Extent of foetal exposure to maternal elexacaftor\/tezacaftor\/ivacaftor during pregnancy","volume":"181","author":"Li","year":"2024","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.arcped.2025.03.005_bib0007","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(24)01134-6","article-title":"Behavioural and sleep issues after initiation of elexacaftor-tezacaftor-ivacaftor in preschool-age children with cystic fibrosis","volume":"404","author":"Sermet-Gaudelus","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.arcped.2025.03.005_bib0008","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1165\/rcmb.2022-0175LE","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor disrupts Respiratory tract development in a murine fetal lung explant model","volume":"67","author":"Lhuillier","year":"2022","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.arcped.2025.03.005_bib0009","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jcf.2018.05.009","article-title":"Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding","volume":"17","author":"Trimble","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.arcped.2025.03.005_bib0010","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jcf.2021.12.004","article-title":"Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor","volume":"21","author":"Collins","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.arcped.2025.03.005_bib0011","article-title":"Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design","volume":"9","author":"Jain","year":"2022","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.arcped.2025.03.005_bib0012","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.chest.2024.09.019","article-title":"Impact of cystic Fibrosis transmembrane conductance regulator modulators on maternal outcomes during and after pregnancy","volume":"167","author":"Jain","year":"2025","journal-title":"Chest"},{"key":"10.1016\/j.arcped.2025.03.005_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1265138","article-title":"Ocular development after highly effective modulator treatment early in life","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.arcped.2025.03.005_bib0014","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jcf.2024.09.007","article-title":"CF ferrets exposed to in utero ivacaftor do not develop lens abnormalities","volume":"24","author":"Taylor-Cousar","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.arcped.2025.03.005_bib0015","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jcf.2022.10.004","article-title":"Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding","volume":"21","author":"Jain","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.arcped.2025.03.005_bib0016","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.arcped.2025.03.005_bib0017","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","article-title":"A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.arcped.2025.03.005_bib0018","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000530261","article-title":"Prenatal Cystic Fibrosis transmembrane conductance regulator modulator therapy: a promising way to change the impact of Cystic fibrosis","volume":"50","author":"Gomez-Montes","year":"2023","journal-title":"Fetal Diagn Ther"},{"key":"10.1016\/j.arcped.2025.03.005_bib0019","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jcf.2020.02.018","article-title":"Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators - an international survey","volume":"19","author":"Nash","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.arcped.2025.03.005_bib0020","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","article-title":"Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation","volume":"20","author":"Taylor-Cousar","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.arcped.2025.03.005_bib0021","article-title":"Experience to date with CFTR modulators during pregnancy and breastfeeding in the British Columbia Cystic Fibrosis clinic","volume":"40","author":"Goodwin","year":"2022","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.arcped.2025.03.005_bib0022","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1055\/a-0973-8565","article-title":"Successful pregnancy of a patient with Cystic Fibrosis genotype F508del\/F508del and progressed pulmonary destruction on lumacaftor\/ivacaftor","volume":"231","author":"Mainz","year":"2019","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.arcped.2025.03.005_bib0023","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.jcf.2019.12.004","article-title":"To be or not to be on CFTR modulators during pregnancy: risks to be considered","volume":"19","author":"Vekaria","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.arcped.2025.03.005_bib0024","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.therap.2022.01.020","article-title":"Pulmonary hemorrhage in a neonate born to a woman with cystic fibrosis treated with targeted cystic fibrosis transmembrane conductance regulator modulator elexacaftor-tezacaftor-ivacaftor during pregnancy","volume":"77","author":"Nuytten","year":"2022","journal-title":"Therapie"},{"key":"10.1016\/j.arcped.2025.03.005_bib0025","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jcf.2024.06.003","article-title":"Clinical outcomes of two infants with cystic fibrosis, including presence of the vas deferens, born to a woman with cystic fibrosis taking CFTR modulators during both pregnancies","volume":"23","author":"Kowalik","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.arcped.2025.03.005_bib0026","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcf.2015.11.013","article-title":"A successful uncomplicated CF pregnancy while remaining on Ivacaftor","volume":"15","author":"Kaminski","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.arcped.2025.03.005_bib0027","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jcf.2021.07.001","article-title":"Drug-induced liver injury from elexacaftor\/ivacaftor\/tezacaftor","volume":"21","author":"Lowry","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.arcped.2025.03.005_bib0028","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and breastfeeding: 3 cases of liver enzymes abnormalities in breastfeed children (PO56)","volume":"23S1","author":"Bergeron","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.arcped.2025.03.005_bib0029","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/j.jcf.2022.01.010","article-title":"Hypervitaminosis A with fulminant secondary intracranial hypertension following personalized medicine-based Elexacaftor\/Tezacaftor\/Ivacaftor initiation in a preadolescent with cystic fibrosis","volume":"21","author":"Wisniewski","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.arcped.2025.03.005_bib0030","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.jcjo.2021.04.018","article-title":"Papilledema and hypervitaminosis A after elexacaftor\/tezacaftor\/ivacaftor for cystic fibrosis","volume":"57","author":"Miller","year":"2022","journal-title":"Can J Ophthalmol"}],"container-title":["Archives de P\u00e9diatrie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929693X2500096X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929693X2500096X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T16:38:59Z","timestamp":1752597539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929693X2500096X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0929693X2500096X"],"URL":"https:\/\/doi.org\/10.1016\/j.arcped.2025.03.005","relation":{},"ISSN":["0929-693X"],"issn-type":[{"value":"0929-693X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preliminary proposals for the follow-up of infants born to mothers with cystic fibrosis treated with CFTR modulators during the first two years of life","name":"articletitle","label":"Article Title"},{"value":"Archives de P\u00e9diatrie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcped.2025.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de p\u00e9diatrie.","name":"copyright","label":"Copyright"}]}}